News
Genital menopause symptoms: What to expect and when to see a doctor

Article produced in association with Spital Clinic
Genitourinary syndrome of menopause (GSM) affects around one in two women after the menopause — and fewer than one in three of those affected ever bring it up with a doctor.
The condition covers a cluster of vaginal, urinary, and sexual symptoms caused by falling oestrogen levels during and after the menopause transition.
It is one of the most common and most treatable consequences of that hormonal shift, and yet it remains one of the least likely topics to come up in a clinical consultation.
What Is Genitourinary Syndrome of Menopause?
The term genitourinary syndrome of menopause replaced older descriptions like atrophic vaginitis and vulvovaginal atrophy because those names missed the point — this condition is not confined to the vagina.
It affects the entire lower genitourinary tract: the vulva, vagina, urethra, and bladder neck, all of which depend on oestrogen to maintain their structure and function.
As oestrogen levels fall during the perimenopause and drop further after the menopause, these tissues change in tangible ways.
The vaginal lining thins; mucus production decreases; vaginal pH rises, making bacterial imbalance more likely; and the cushioning fat tissue around the vulva diminishes.
Crucially, these changes are progressive — without treatment, they continue to worsen rather than settling on their own.
NICE guideline NICE guideline NG23: Menopause — identification and management, updated in November 2024, defines genitourinary symptoms as a core part of the menopause syndrome. The guidelines support active treatment across all severity levels — not just when symptoms are severe.
The Full Symptom Picture: Genital, Urinary and Sexual
Genital symptoms are the most widely recognised.
Vaginal dryness is the most common, affecting up to 93 per cent of women with GSM — and described as moderate to severe in 68 per cent of those affected.
Other symptoms include burning, itching, soreness, and unusual or offensive discharge caused by changes in the vaginal environment.
The tissue can become fragile enough to bleed from minor friction, including during a gynaecological examination.
Urinary symptoms arise because the urethra and bladder neck are equally dependent on oestrogen.
These include needing to urinate more often or urgently, waking in the night to urinate, pain or burning when urinating, recurrent urinary tract infections, and stress incontinence — leakage triggered by coughing, sneezing, or exercise.
Many women with recurrent UTIs are treated again and again with antibiotics without the underlying GSM ever being identified or addressed.
Sexual symptoms complete the picture: painful intercourse from reduced lubrication and tissue fragility, spotting or bleeding after sex, and reduced arousal, lubrication, and ability to orgasm.
These changes are physical in origin, not psychological — though if symptoms go unmanaged for long enough, the two often start to reinforce each other.
Prevalence data from North Tees and Hartlepool NHS Foundation Trust shows that vaginal dryness affects around one in four women in the lead-up to the menopause, rising to one in two after it, and approximately seven in ten women in their seventies.
Symptoms can begin during the perimenopause — well before periods have stopped.
Anyone noticing these changes can seek assessment through a GP or NHS sexual health service — or through a private gynaecology specialist.
Why GSM Does Not Improve Without Treatment
Unlike hot flushes and night sweats — which typically ease over two to five years — genitourinary symptoms do not improve over time and return once treatment stops.
They are chronic and progressive: the longer they go untreated, the more entrenched the underlying tissue changes become.
This makes the gap between prevalence and treatment especially significant.
Around 70 per cent of women with GSM symptoms never raise them with a healthcare professional, and only 4 per cent to 35 per cent use any form of treatment — partly from embarrassment, partly because many assume nothing can be done.
A condition with safe, effective, NICE-recommended treatments goes largely unmanaged.
First-Line Self-Care: Moisturisers, Lubricants and OTC Options
Vaginal moisturisers — such as Replens, Regelle, and Sylk gel — differ from vaginal lubricants: they are for regular, ongoing use (typically two to three times per week) to maintain tissue hydration.
They do not treat the underlying hormonal cause, but are effective at reducing dryness and discomfort and are NICE NG23-supported as first-line non-hormonal management.
Vaginal lubricants are for use during sexual activity. Water-based lubricants are compatible with latex condoms and diaphragms; oil-based products are not. Both are available over the counter and are a reasonable first step for mild or early symptoms.
NICE NG23 supports their use alongside vaginal oestrogen, and recommends them as the primary option when hormonal treatment is not suitable.
Vaginal Oestrogen and Prescription Treatments
For symptoms that persist beyond a few weeks of self-care, or that are moderate to severe from the outset, NICE NG23 sets out the evidence-based first-line treatment: offer vaginal oestrogen to anyone with genitourinary symptoms associated with the menopause — including those already using systemic HRT — and review regularly.
Vaginal oestrogen restores oestrogen levels in local tissue without significant absorption into the wider body.
NHS information on vaginal oestrogen confirms it does not carry the same risks as systemic HRT — the dose is low and very little reaches the general circulation, which matters for women who have been advised against systemic treatment. It comes as a tablet, pessary, cream, gel, or ring.
NICE NG23 specifically recommends vaginal oestrogen for women already using systemic HRT as well as those who are not — recognising that between 10 per cent and 25 per cent of women on systemic HRT still experience genitourinary symptoms that systemic treatment alone does not fully address.
Two further prescription options are available for women who cannot use vaginal oestrogen or have not responded to it.
Prasterone — a DHEA vaginal pessary — is recommended by NICE NG23 when vaginal oestrogen or non-hormonal treatments have not worked or are not tolerated.
Ospemifene, an oral tablet, is recommended where locally applied treatments are not practical — for example, due to physical disability.
Choosing between these options involves a clinical review of individual history, any contraindications, and personal preference.
A BMS-accredited private menopause assessment can provide that review alongside a full discussion of treatment options.
On laser therapy: the RCOG Scientific Impact Paper No. 72 concluded that vaginal laser treatment for GSM should not be offered outside of randomised controlled trials, and NICE NG23 takes the same position.
For women with a history of breast cancer, non-hormonal moisturisers and lubricants come first; vaginal oestrogen may be considered if those are ineffective, but only with the involvement of the treating oncologist.
When to See a Doctor
The NHS recommends seeking assessment when genital menopause symptoms have persisted for more than a few weeks despite self-care, when they are affecting daily life or sexual function, or when they involve post-menopausal bleeding, unusual discharge, or recurrent urinary tract infections.
Post-menopausal bleeding always warrants prompt GP review. It should not be assumed to be friction-related or attributable to GSM without a clinical examination — it is a red flag symptom that requires investigation to rule out other causes.
Recurrent UTIs in a postmenopausal woman — particularly without an obvious cause — are worth assessing for an underlying GSM component, rather than treating with repeated antibiotic courses alone.
A GP can initiate first-line treatment; for more complex presentations or where initial management has not helped, a menopause specialist can offer a more thorough evaluation.
The shift from terms like atrophic vaginitis to genitourinary syndrome of menopause reflects something important: these are medical symptoms, not a normal inconvenience to be quietly endured.
Effective treatment exists at every level of severity — from OTC moisturisers through to NICE NG23-recommended prescription options.
Anyone whose symptoms are affecting quality of life can see an NHS GP, or book a private menopause assessment with a BMS-accredited specialist.
The gap is not in what medicine can offer — it is in how reliably those options reach the women who need them.
This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment. Clinical guidance referenced reflects published NHS and NICE standards as at March 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article. This piece was produced in association with Spital Clinic, which provided background clinical information for editorial purposes. Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.
News
EU healthcare’s gender pay gap hits 19%, WHO report finds

Women in Europe’s health and care sector face a 19 per cent hourly gender pay gap, according to a new World Health Organization (WHO) report.
Women account for 77 per cent of the sector’s workforce, compared with 45 per cent across all other sectors combined, but make up only 55 per cent of its top earners.
The hourly gender pay gap widens at higher wage levels, from 2 per cent among the lowest earners to more than 22 per cent at the top.
The WHO report found that health and care accounts for almost 17 per cent of all women’s employment in its European Region, compared with 5 per cent of men’s employment.
The sector is the fourth-largest employer overall and the single largest employer of women in the region.
Natasha Azzopardi Muscat, director of the Division for Health Systems at WHO Europe, said: “Women make up the majority of the people who keep Europe’s health systems running, yet they’re paid less than their male counterparts, a gap that compounds over a lifelong career.”
The findings follow a pattern seen across the wider labour market, with structural inequality increasing at higher wage and seniority levels.
Globally, women working in health earn an average of 24 per cent less than men, according to the report, a wider gap than in many other industries.
Some of the difference in pay could be explained by work-related factors, including age, education, public or private sector employment and whether people worked full-time or part-time.
After adjusting for those four factors, the hourly pay gap fell from 19 per cent to 6 per cent, while the monthly gap declined from 28 per cent to 10 per cent.
The remaining difference could not be explained by factors measured in the data.
“Most of this gap isn’t down to women working fewer hours, being younger or working in different parts of the sector,” Azzopardi Muscat said.
“It comes down to how the sector values women’s work. Age, education, working hours and public versus private sector employment only helps explain some of it.”
WHO said the findings point to factors including the undervaluation of care work, occupational segregation and potential discrimination in pay-setting practices.
Occupational categories with a higher proportion of women paid less across managerial, professional and technical roles.
Management jobs in health and care employ more women than management roles in other sectors and pay an average of €22 per hour, compared with €24.70 in comparable roles elsewhere.
WHO described the gender pay gap as one of the most persistent forms of labour market inequality. Given the number of women working in health and care, it said the gap could have important economic and social consequences.
The report said the inequality may lead to lower lifetime earnings and pension entitlements, increase women’s risk of poverty, reduce returns to education and undermine sustainable economic growth.
“It means lower pensions, less financial security in older age, and a higher risk of poverty for women who’ve spent their working lives caring for others,” said Azzopardi Muscat.
“This isn’t a coincidence, and it isn’t about qualifications. Women are being paid less for the same work and passed over for the roles that pay more.”
WHO said closing gender pay gaps was both an equity imperative and an investment in a stronger and more sustainable health workforce.
It suggested measures including greater salary transparency, increased female representation in decision-making roles and action to address gender norms and stereotypes.
Ageing
Higher BMI in early adulthood linked to lower breast cancer risk after menopause

Higher BMI at 20 was linked to a lower risk of post-menopausal breast cancer in an analysis of more than 33,000 women.
Lower breast density later in life may partly explain the link between higher body mass index, or BMI, in early adulthood and lower breast cancer risk after menopause.
The findings could help explain why higher body weight in childhood, adolescence and early adulthood appears linked to lower long-term risk, while being overweight in middle age is associated with increased breast cancer risk.
First author Dr Benoit Jauniaux, a surgical trainee in the North-West Deanery, said: “Researchers in previous studies have observed that women with a higher BMI in childhood or their early adulthood appear to have a lower risk of breast cancer after the menopause, but we have not fully understood why.
“This study suggests that downstream changes to breast density may explain a large part of this effect.”
The study was published in the British Journal of Cancer on 17 September 2026 and was supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC): Manchester.
Researchers at The University of Manchester and Manchester University NHS Foundation Trust followed 33,816 women taking part in the UK Predicting Risk of Cancer at Screening (PROCAS) programme for more than a decade.
They recorded 1,261 cases of post-menopausal breast cancer and compared women’s self-reported BMI at age 20 with breast density measurements from routine mammograms.
Breast density refers to the amount of fibrous and glandular tissue compared with fatty tissue in the breast. Women with denser breasts are known to have a higher risk of breast cancer.
Women with a higher BMI at age 20 generally had lower percentage breast density later in life and were less likely to develop post-menopausal breast cancer.
For every five-point increase in BMI at age 20, the risk of developing post-menopausal breast cancer fell by around 15 per cent. Further analysis suggested lower breast density may account for almost 60 per cent of this effect.
Researchers believe the timing of body weight gains may be crucial because women’s breasts are still developing during adolescence and early adulthood, potentially leading to long-term changes in tissue structure.
The study also found that different measures of breast density may reflect different biological pathways linked to breast cancer risk.
One measure, estimating the percentage of dense tissue within the breast, appeared to capture some of the lasting effects associated with higher body weight in early adulthood. Another measure, based on the total volume of glandular tissue, appeared to be more strongly influenced by body weight later in life.
Senior author Professor Andrew Renehan is professor of cancer studies and surgery at The University of Manchester and programme co-lead in the Cancer Prevention and Early Detection Theme at the NIHR BRC: Manchester/
The researcher said: “These findings do not suggest that gaining weight is protective.
“What they offer is further insight into how breast tissue and consequent breast cancer risk may be shaped across a woman’s lifetime, and we want to understand these mechanisms further.
“Maintaining a healthy weight remains important, because excess weight in later adulthood is linked to a higher risk of breast cancer and many other serious diseases.
“But this study adds to growing evidence that exposures during early life can have lasting effects on health decades later.”
Mental health
Neuroscience-backed journaling for women’s mental health

AI-powered journaling app Véa is supporting mental health by helping women to understand their thoughts, triggers and behavioural patterns.
Winner of the Brain and Mental Health Innovation Award at this year’s Femtech World Awards, Véa is designed to address the emotional gap in women’s health technology.
The journal – which has been built by a female team and trained on women’s health papers – tracks inner states, provides personalised insights and somatic practices, and utilises AI to explain complex neuroscience in relatable terms.
Described by its founders as a “protector, seeker, and sculptor”, Véa provides a longitudinal map of women’s emotional journeys, integrating journaling with therapy and both in-person and online community support.
The journal’s goal is to improve women’s mental health without replacing professional care.
Zahra Bhatti, co-founder and CEO and Katrina Zalcmane , co-founder and growth lead speak to Femtech World about the technology, winning a Femtech World Award and their plans for the future.
Women’s health and wellbeing technology has grown so rapidly over the last few years, but is largely focused around physical health. What was the emotional gap that you saw that inspired you to create the journal?
“Women’s health has been focused on reproductive health and physical health, but it is all one ecosystem – it always starts with the mind,” says Zahra.
“Whatever you feel down here, you feel up there too, and the hormones reflect that.
“With Véa, it was actually built from our own personal experience of burnout.
“We wanted to make a space where women could feel safe and were able to reflect what’s on their mind, but also understand their mind the same way that women understand their hormones.
“Women need to understand what happens in our minds. Véa helps women to understand cognitive distortions, why they feel the way they feel, black and white thinking – we wanted to really surface that for them.
“For example, when you’re in your luteal phase, your serotonin levels drop, so that means you’re going to be a bit more nervous.
“You’re going to be more reactive. You’re going to be taking things more deeply, and that’s something that your rational mind wouldn’t normally do if you’re in your ovulation phase.
“So that’s what Véa does – she reflects that back to you, so you understand your body and thought processes.”
Véa describes itself as a journal that’s designed for the female mind. What does that mean in practice, and how does the experience differ from using traditional journaling?
“The majority of our team is female, so Véa has been built from all of our lived experiences, and the AI itself is trained on women’s health papers,” says Katrina.
“It takes into account what having a certain condition means for individuals. For example, if you have endometriosis or PCOS, We’ve trained our AI on womens health data and research, which gets reflected back to the woman in a simple and effective way
“We have a clinical board, who are all also women, who look through the AI and the language. They ensure that all outputs are evidence based, ethical and take into account the various therapies which are proven to work for women.
“We also have somatic practices which are focused on women which we call “rituals”. We have a self-inquiry ritual, a confidence mirror ritual, or we have one of our psychotherapists on the board who does therapy through novels, for example.
“These aim to make you the protagonist of your story.
“Generic journaling apps are one size fits all, but women are not one size fits all, and that’s what we’ve made sure to put in the forefront of Véa.”
Instead of conventional mood tracking, you are focused on the inner states of women. How do you develop that approach, and what kind of insights has it revealed about how women reflect on their emotions?
Katrina says: “Mood plays a part in our inner state and Véa checks in on that.
“It allows you to have a journey across time. For example, on a good day, maybe their “protector” aspect is good at setting boundaries, but on a bad day, it could be really closed off.
“It’s a richer approach, and these inner states are tied to specific prompts which are then linked in the journaling.”
“As women, we are fluid,” adds Zahra.
“We are not one entity.
“For example, you might be in a state where you’re really overthinking, but actually, you’re seeking new perspectives, and that’s why within Véa, the inner state is called a “seeker”.
“When you converse with Véa in your seeker mode, she will challenge you in a Socratic way.
“However, the next day, you might be a “protector”, and then Véa will adjust her voice for a reflective and exploratory tone compared to when you were a seeker.
“Another state which I love is the “sculptor” which is when you’re feeling confident.
“When you’re a sculptor, Véa will talk about how you can be creative, asking questions such as ‘what did you create today?’ ‘How did that make you feel?’ and ‘How would you describe that if you could put a shape to this color, this feeling?’, for example.
“Véa goes into all of these different modes, and it builds a longitudinal map of the woman as well. So, throughout weeks, months and years, you can see how you’ve changed across time.”
How did you approach designing an AI companion that feels supportive without replacing human connection or professional care?
“For the past six years, I’ve been a product manager. So I’ve seen how all of these web apps and applications have been built, and I’ve worked quite deeply with AI so I knew what was missing and like what women truly needed,” says Zahra.
“The key thing for us is that we want to bring “URL to IRL” [in real life].
“We have a community that goes alongside Véa. This includes a WhatsApp community and events.
“We turn the rituals inside Véa into in-person workshops at our events with our clinical board and with professionals in the space.
“We are not neuroscientists, but there are neuroscientists who have helped us build the app, and we make sure that AI is there to support you, but AI will never replace that human touch.
“That’s something that’s very close to us, and we want to make sure we connect people together and help people reflect in a safe space.
“As well as AI, there is the option to talk to the clinical board, to use their rituals, to reflect with the community, and go to our events.”
Katrina adds: “The key is that whatever the touch point is, whether it’s the app or it is an event or even our online community, we don’t want women to feel alone. We want them to feel together, grow together, and process together.”
People may often start journaling with good intentions, but struggle to stick with the practice. What have you learned about building habits and how those insights have shaped the experience of your product?
Zahra says: “I think everyone wants to gamify things – what helps us is the community aspect.
“We’ve created a tribe through the community, and because it’s so hyper personalised, you help shape the app, the app doesn’t shape you. You have full control, which makes people want to come back.
“Véa remembers what you said yesterday as well as six weeks ago, and she will surface that.
“We do have “streaks”, but our streaks are very gentle – every time you get a streak, you get a neuroscience fact along with it.
“Something else we have built in that helps retention is “breakthroughs”. When Véa detects a shift in language, and will highlight, for example, that you have shifted from overthinking to certainty.”
“I think people are sick of data, they’re sick of data that they can’t interpret from. Véa interprets for you.
“Soon we will evolve even more and add more features such as cycle tracking, wearable tracking and hormone tracking, to build out that ecosystem.”
What does success look like for Véa and how do you see the app and the community evolving as you move forward?
“We want to launch across so many different markets. Our next target is the US,” explains Katrina.
“We want to bring our events over there as well. We do a lot of corporate events too. We have one with NatWest coming up – we know that work stress is a big thing, especially amongst females.
“I think there’s a real space for that in the corporate world, so that’s one of our key focuses.”
Zahra adds: “Growing in markets and keeping going with our communities. We have just launched a supper club which sold out in three days in Manchester, which is absolutely amazing. We’re doing some in London and Amsterdam as well in the next few months. We are focused on growth, growing our board as well, and keeping the female mind at the center.”
What does it mean to win the Femtech World Award?
Katrina says: “When you are so passionate and truly believe in something, you do it for that reason, but that external validation of seeing that it also matters for others in the wider space means so much.
“Especially, in Femtech – it is a whole category that has been growing, but when it comes to funding and recognising women’s issues, there is still a lot of awareness that needs to be raised.
“Being recognised gives us that fuel to continue and drive forward, and that it really does matter.”
“We want to be at the forefront of women’s mental wellness as a whole, and have put many sleepless nights into developing the app, so it is a big testament to that,” adds Zahra.
Menopause1 week agoMenopause may not explain rising heart condition in women – study
Entrepreneur2 weeks agoLast chance to save on Women’s Health Week and Women’s Sport Summit: Early Bird pricing ends 11 September
Fertility2 weeks agoParacetamol use may impact future fertility, studies suggest
Insight1 week agoWomen with birth trauma face 2.5x higher healthcare costs – study
Cancer2 weeks agoCancer drug could tackle osteoporosis menopause weight gain
News7 days agoMedical cannabis may improve endometriosis symptoms – study
Cancer1 week agoStudy could explain why obesity is a breast cancer risk factor
Diagnosis2 weeks agoFDA approves AstraZeneca breast cancer drug











